Abstract
DB-289, an oral diamidoxime prodrug of DB-75 from the University of North Carolina, Georgia State University, Auburn University and Duke University, is being developed by Immtech International as a potential treatment for Pneumocystis carinii pneumonia (PCP), tuberculosis, trypanosomiasis and malaria.
MeSH terms
-
Animals
-
Antimalarials / adverse effects
-
Antimalarials / chemistry
-
Antimalarials / pharmacokinetics
-
Antimalarials / therapeutic use
-
Antiprotozoal Agents / adverse effects
-
Antiprotozoal Agents / chemistry
-
Antiprotozoal Agents / pharmacokinetics
-
Antiprotozoal Agents / therapeutic use*
-
Antitubercular Agents / adverse effects
-
Antitubercular Agents / chemistry
-
Antitubercular Agents / pharmacokinetics
-
Antitubercular Agents / therapeutic use*
-
Benzamidines / adverse effects
-
Benzamidines / chemistry
-
Benzamidines / metabolism
-
Benzamidines / pharmacokinetics
-
Benzamidines / therapeutic use*
-
Clinical Trials, Phase I as Topic
-
Clinical Trials, Phase II as Topic
-
Humans
-
Prodrugs / adverse effects
-
Prodrugs / chemistry
-
Prodrugs / pharmacokinetics
-
Prodrugs / therapeutic use*
-
Structure-Activity Relationship
-
Trypanocidal Agents / adverse effects
-
Trypanocidal Agents / chemistry
-
Trypanocidal Agents / pharmacokinetics
-
Trypanocidal Agents / therapeutic use
Substances
-
Antimalarials
-
Antiprotozoal Agents
-
Antitubercular Agents
-
Benzamidines
-
Prodrugs
-
Trypanocidal Agents
-
furamidine
-
pafuramidine